Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effect of Baricitinib Suspension vs Tablet
NCT03212638Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2017
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of baricitinib in juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA) (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Drug Concentration, Area Under the Concentration Versus Time Curve From Time Zero to Last Measurable Concentration and 1 more. Started Jun 2017; status: completed.
02
Drugs
baricitinib
03
Conditions
juvenile idiopathic arthritis (JIA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03212638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03212638.